The premium GLP-1 companion. Tesamorelin targets visceral fat while Ipamorelin supports growth hormone pulsatility, lean muscle preservation, recovery, and metabolic balance — designed for body recomposition.
The Recomposition Protocol combines two growth hormone–modulating peptides with complementary mechanisms. Tesamorelin is an FDA-approved GHRH analogue studied for visceral fat reduction. Ipamorelin is a selective ghrelin mimetic that promotes physiologic growth hormone pulses without significant effects on cortisol or prolactin.
Tesamorelin preferentially targets visceral adipose tissue and supports fat redistribution. Ipamorelin enhances natural GH pulsatility, supporting lean muscle retention, recovery, sleep quality, and overall metabolic efficiency. Together, they create a synergistic environment for body recomposition while minimizing overstimulation of the GH axis.
Women on or recently completing GLP-1 therapy, or those focused on visceral fat reduction, lean muscle preservation, improved recovery, and optimized body composition.
Many patients use this protocol alongside GLP-1 medications. Your provider will review your medications and confirm compatibility before prescribing.
No — Ipamorelin supports physiologic GH pulsatility associated with lean mass preservation and recovery, helping counteract GLP-1–related muscle loss.
Early changes typically appear in 8–12 weeks, with more pronounced visceral fat reduction and recomposition by 3–6 months.
Yes — baseline IGF-1 testing is typically required before prescribing. Labs are ordered to LabCorp or reviewed if recently completed.
Compounded peptides are prescribed off-label under medical supervision for wellness and body composition goals.
Not FDA-approved. Prepared by state-licensed 503A pharmacies under USP standards.
May interact with insulin, hormone therapies, and metabolic medications.
Subcutaneous injection with provider training included.